## Prevent Cancer Foundation® Advocacy Workshop 2020 Speaker Bios:

**Keynote – Heather Hampel, Associate Director, Division of Human Genetics; Associate Director, Biospecimen Research; Professor, Internal Medicine; Licensed Genetic Counselor the Ohio State University Comprehensive Cancer Center**

Heather is a Professor in the Department of Internal Medicine and Associate Director of the Division of Human Genetics. She coordinated the Columbus-area Lynch syndrome study that determined the frequency of Lynch syndrome among newly diagnosed patients with these cancers. She is the PI of the Ohio Colorectal Cancer Prevention, a statewide study to identify patients with hereditary cancer syndromes and provide cascade testing to their at-risk family members. Heather was the Region IV Representative on the Board of Directors of the National Society of Genetic Counselors in 2003-4. She was on the Board of Directors for the American Board of Genetic Counseling from 2006-2011, serving as President in 2009 and 2010. She has been on the Steering Committee of the National Colorectal Cancer Roundtable since 2016. She was on the Council of the Collaborative Group of the Americas on Inherited Colorectal Cancer from 2016-2019, serving as president in 2017-2018. She was just elected Secretary/Treasurer Elect of the National Society of Genetic Counselors with her term starting in 2021.

<u>Panel Speakers</u>

**Moderator: Lisa Schlager, Vice President, Public Policy, Facing Our Risk of Cancer Empowered**

Lisa Schlager is a recognized consumer advocacy leader for the hereditary cancer community. As Vice President of Public Policy, Ms. Schlager spearheads the organization's legislative and regulatory policy efforts, advocating for the unique needs people who carry inherited genetic mutations, which increase their risk of cancer, and the broader high-risk cancer community.

Well-versed in health care and genetic privacy laws—i.e. Genetic Information Nondiscrimination Act (GINA), Women's Health and Cancer Rights Act (WHCRA), Affordable Care Act, etc.—Schlager is the point person on national guidelines and advocacy issues affecting the hereditary cancer community. She possesses expert

knowledge on policies affecting, and insurance coverage of, screening and preventive services for individuals at increased risk of cancer and targeted treatments for those diagnosed with hereditary cancers.

Ms. Schlager holds leadership positions with numerous cancer and health care initiatives in the government, nonprofit, and private sectors. In recent years, she has served as a Co-Chair of the PCORnet Patient & Consumer Engagement Steering Committee; Project Manager for the ABOUT Patient-Powered Research Network; Partner Manager for the CDC-funded XRAYS program; Executive Committee Member of the FDA Breast Device Collaborative Community; Patient Consultant on the PCORI Genomic Sequencing Report, and more. She also represents FORCE and the hereditary cancer community as an expert speaker in the media, at conferences and events.

**Jennifer R. Leib, Founder, Innovation Policy Solutions, LLC**

Jennifer is the founder of Innovation Policy Solutions, a government relations firm specializing in genomics and precision medicine policy. Jennifer's clients are innovators of disruptive technologies that are fundamentally changing the way research is done, the way medicine is practiced, and the way health care is delivered. She helps clients navigate the evolving regulatory and reimbursement landscape for targeted therapeutics, laboratory-based diagnostics, and mobile and digital health technologies. Jennifer also specializes in assisting young companies and associations with building a brand presence in Washington through relationship building with advocates and policymakers. Some of her accomplishments include leading the advocacy effort in support of the plaintiffs in the Supreme Court's unanimous decision in the Association for Molecular Pathology vs. Myriad Genetics Inc. that invalidated gene patents, serving on the Executive Committee of the Coalition for Genetic Fairness which successfully advocated for passage of the Genetic Information Nondiscrimination Act, and more recently, working with a coalition of stakeholders to secure reimbursement for diagnostic tests with and without emergency use authorization for COVID-19.

Prior to launching Innovation Policy Solutions, Jennifer co-founded another consulting firm, HealthFutures, which was acquired by CRD Associates in 2009. Board certified in genetic counseling, she previously worked at the National Institutes of Health, the Senate Committee on Health, Education, Labor and Pensions, and in the biotechnology industry. Jennifer holds a master's degree in genetic counseling from The Johns Hopkins University and a bachelor's degree with honors and high distinction in sociology from the University of Michigan.

**Nikki Martin, Director of Precision Medicine Initiatives, LUNGevity**

Nikki Martin is Director of Precision Medicine Initiatives where she focuses on accelerating access to precision medicine for lung cancer patients. She is passionate about the need for members of the cancer community to work together to address common gaps in access to biomarker testing, and has been leading a multilateral coalition of 50 organizations to adopt consistent terms for testing in precision medicine in order to help eliminate patient confusion about the type of testing they need for their cancer. Prior to joining LUNGevity, Nikki worked in Alliance & Advocacy Relations at Genentech where she championed awareness of unmet needs and driving change in the patient community. Nikki held two roles at Grifols/Novartis Diagnostics in Global Communications and also in Global Public Affairs. In those roles, she worked with global partners including sickle cell disease, hemophilia, and thalassemia patient advocacy groups, the Pan American Health Organization (PAHO), and the Asia Pacific Economic Cooperation (APEC) to educate the public, policy makers and other stakeholders on improving transfusion safety. She started her career in Japan where she worked at Cosmo PR advising healthcare clients on public relations activities in the Japanese market. She earned her MA in Commercial Diplomacy from the Monterey Institute of International Studies (now the Middlebury Institute of International Studies), and a BS in Anthropology and BA in Spanish from Santa Clara University. Nikki lives in Davis, CA with her wife and two dogs, Mia and Stuart.

**Becky Nagy, Vice President of Medical Affairs, Guardant**

Ms. Nagy is a licensed genetic counselor and Vice President of Medical Affairs at Guardant Health, Inc. Prior to joining Guardant, she was an Associate Professor in the Department of Clinical Internal Medicine at the Ohio State University James Cancer Hospital. She has over 15 years of experience in counseling patients with hereditary cancer syndromes and extensive experience in translational research in both germline and somatic genomics. She is a past president of the National Society of Genetic Counselors and continues her leadership role in the NSGC as co-director of the NSGC Leadership Development Program.

**Brandi Preston, Founder, Kamie K. Preston Hereditary Cancer Foundation**

Brandi was born and raised in Omaha, Nebraska. She is the founder of a non-profit organization in memory of her mother, Kamie Preston. The organization aims to raise awareness about hereditary cancer syndromes while improving access to genetic testing.

Kamie was only 35 years old when she was diagnosed with aggressive breast cancer. Brandi spent many summers babysitting her brother Ben and sister Bailey in hospital waiting rooms as their mother underwent chemotherapy and radiation treatments. It was in those hospital rooms Brandi learned about the genetic mutation her mother carried, a mutation she had a 50/50 chance of also having.

As the cancer progressed, Kamie began to prepare her children for life without her. In addition to a mother's typical expectations for going to college and looking out for each other, Kamie asked each of her children to learn their risk, to be proactive with their health rather than reactive.

Kamie passed away on July 27, 2005. She was 40 years old, her children only 14, 13, and 9 years old. Since then, Brandi has fulfilled the promise she made at her mother's bedside. On her 19th birthday she had genetic testing and learned that she too carries the BRCA1 mutation, giving her an 87% lifetime risk of breast cancer and 63% lifetime risk of ovarian cancer